Jose Victor Zambrana

Mr. Jose Victor Zambrana

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ABAngel Balmaseda
Angel Balmaseda
KSKarin Stettler
Karin Stettler
RMRaquel Medialdea-Carrera
Raquel Medialdea-Carrera
DCDamaris Collado
Damaris Collado
XJXia Jin
Xia Jin
DCDavide Corti
Davide Corti
Zika virus (ZIKV) is a mosquito-borne flavivirus that emerged recently as a global health threat, causing a pandemic in the Americas. ZIKV infection mostly causes mild disease, but is linked to devastating congenital birth defects and Guillain-Barré syndrome in adults. The high level of cross-reactivity among flaviviruses and their cocirculation has complicated serological approaches to differentially detect ZIKV and dengue virus (DENV) infections, accentuating the urgent need for a specific and sensitive serological test. We previously generated a ZIKV nonstructural protein 1 (NS1)-specific human monoclonal antibody, which we used to develop an NS1-based competition ELISA. Well-characterized samples from RT-PCR-confirmed patients with Zika and individuals exposed to other flavivirus infections or vaccination were used in a comprehensive analysis to determine the sensitivity and specificity of the NS1 blockade-of-binding (BOB) assay, which was established in laboratories in five countries (Nicaragua, Brazil, Italy, United Kingdom, and Switzerland). Of 158 sera/plasma from RT-PCR-confirmed ZIKV infections, 145 (91.8%) yielded greater than 50% inhibition. Of 171 patients with primary or secondary DENV infections, 152 (88.9%) scored negative. When the control group was extended to patients infected by other flaviviruses, other viruses, or healthy donors (n = 540), the specificity was 95.9%. We also analyzed longitudinal samples from DENV-immune and DENV-naive ZIKV infections and found inhibition was achieved within 10 d postonset of illness and maintained over time. Thus, the Zika NS1 BOB assay is sensitive, specific, robust, simple, low-cost, and accessible, and can detect recent and past ZIKV infections for surveillance, seroprevalence studies, and intervention trials. Significance Zika virus (ZIKV), a mosquito-borne flavivirus with homology to dengue virus (DENV), has become a public health threat, particularly because of its association with severe congenital birth defects. The high level of cross-reactivity among flaviviruses and their cocirculation has complicated serological approaches to detect ZIKV infections. Thus, there is an urgent need for a specific serological assay to discriminate ZIKV infection from other flaviviruses. This study demonstrates that the antibody-based assay we developed and implemented in five countries has high specificity and sensitivity in the detection of recent and past ZIKV infections. The ZIKV nonstructural protein 1 (NS1) blockade-of-binding ELISA assay is a simple, robust, and low-cost solution for Zika surveillance programs, seroprevalence studies, and intervention trials in flavivirus-endemic areas.

27 August 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JZJose Victor Zambrana
Jose Victor Zambrana
FCFausto Bustos Carrillo
Fausto Bustos Carrillo
RBRaquel Burger-Calderon
Raquel Burger-Calderon
DCDamaris Collado
Damaris Collado
NSNery Sanchez
Nery Sanchez
EHEva Harris
Eva Harris
In 2015, a Zika epidemic in Brazil began spreading throughout the Americas. Zika virus (ZIKV) entered Managua, Nicaragua, in January 2016 and caused an epidemic that peaked in July–September 2016. ZIKV seropositivity was estimated among participants of pediatric (n = 3,740) and household (n = 2,147) cohort studies, including an adult-only subset from the household cohort (n = 1,074), in Managua. Seropositivity was based on a highly sensitive and specific assay, the Zika NS1 blockade-of-binding ELISA, which can be used in dengue-endemic populations. Overall seropositivity for the pediatric (ages 2–14), household (ages 2–80), and adult (ages 15–80) cohorts was 36, 46, and 56%, respectively. Trend, risk factor, and contour mapping analyses demonstrated that ZIKV seroprevalence increased nonlinearly with age and that body surface area was statistically associated with increasing seroprevalence in children. ZIKV seropositivity was higher in females than in males across almost all ages, with adjusted prevalence ratios in children and adults of 1.11 (95% CI: 1.02–1.21) and 1.14 (95% CI: 1.01–1.28), respectively. No household-level risk factors were statistically significant in multivariate analyses. A spatial analysis revealed a 10–15% difference in the risk of ZIKV infections across our 3-km-wide study site, suggesting that ZIKV infection risk varies at small spatial scales. To our knowledge, this is the largest ZIKV seroprevalence study reported in the Americas, and the only one in Central America and in children to date. It reveals a high level of immunity against ZIKV in Managua as a result of the 2016 epidemic, making a second large Zika epidemic unlikely in the near future. Significance Seroprevalence studies are important for determining risk factors for infection and for assessing the susceptible fraction of a population after an epidemic has swept through a population. Here, Zika virus (ZIKV) seroprevalence was estimated among participants of a pediatric cohort, a separate household cohort, and an adult-only subset from the household cohort, in Managua, Nicaragua, after the 2016 Zika epidemic, yielding 36, 46, and 56% seropositivity, respectively. To our knowledge, this is the only ZIKV seroprevalence study reported in Central America and the largest in the Americas and in a pediatric population to date. The explosive 2016 Zika epidemic resulted in a high level of seropositivity to ZIKV, making a second large Zika epidemic in Managua in the near future unlikely.

9 January 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SBSANDRA BOS
SANDRA BOS
AGAaron L. Graber
Aaron L. Graber
JCJaime A. Cardona-Ospina
Jaime A. Cardona-Ospina
EDElias M. Duarte
Elias M. Duarte
JZJose Victor Zambrana
Jose Victor Zambrana
EHEva Harris
Eva Harris
Dengue viruses (DENV1–4) are the most prevalent arboviruses in humans and a major public health concern. Understanding immune mechanisms that modulate DENV infection outcome is critical for vaccine development. Neutralizing antibodies (nAbs) are an essential component of the protective immune response, yet their measurement often relies on a single cellular substrate and partially mature virions, which does not capture the full breadth of neutralizing activity and may lead to biased estimations of nAb potency. Here, we analyze 125 samples collected after one or more DENV infections but prior to subsequent symptomatic or inapparent DENV1, DENV2, or DENV3 infections from a long-standing pediatric cohort study in Nicaragua. By assessing nAb responses using Vero cells with or without DC-SIGN and with mature or partially mature virions, we find that nAb potency and the protective NT50 cutoff are greatly influenced by cell substrate and virion maturation state. Additionally, the correlation between nAb titer and protection from disease depends on prior infection history and infecting serotype. Finally, we uncover variations in nAb composition that contribute to protection from symptomatic infection differently after primary and secondary prior infection. These findings have important implications for identifying antibody correlates of protection for vaccines and natural infections.

1 March 2018 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
ABAngel Balmaseda
Angel Balmaseda
JZJose Victor Zambrana
Jose Victor Zambrana
DCDamaris Collado
Damaris Collado
NGNadezna García
Nadezna García
SSSaira Saborío
Saira Saborío
EHEva Harris
Eva Harris
Zika virus (ZIKV) is a mosquito-borne flavivirus that is responsible for recent explosive epidemics in the Americas. Notably, ZIKV infection during pregnancy has been found to cause congenital birth defects, including microcephaly, and ZIKV has been associated with Guillain-Barré syndrome in adults. Diagnosis and surveillance of Zika in the Americas have been challenging due to similar clinical manifestations and extensive antibody cross-reactivity with endemic flaviviral diseases, such as dengue. We evaluated four serological and two reverse transcription-PCR (RT-PCR) methods in acute-phase (mean day, 1.8), early-convalescent-phase (mean day, 16.7), and late-convalescent-phase (mean, ~7 months) samples from the same individuals in a long-term pediatric cohort study in Nicaragua. Well-characterized samples from 301 cases of Zika, dengue, or non-Zika, nondengue febrile illnesses were tested. Compared to a composite reference, an in-house IgM antibody capture enzyme-linked immunosorbent assay (MAC-ELISA) and the NIAID-Biodefense and Emerging Infections (BEI) MAC-ELISA measuring IgM yielded sensitivities of 94.5% and 70.1% and specificities of 85.6% and 82.8%, respectively. The NS1 blockade-of-binding ELISA measuring anti-ZIKV NS1 antibody levels yielded sensitivities of 85.0% and 96.5% and specificities of 91.4% and 92.6% at early and late convalescence, respectively. An inhibition ELISA detecting total anti-ZIKV antibodies had sensitivity and specificity values of 68.3% and 58.3% for diagnosis and 94.0% and 98.6% for measuring annual infection incidence. Finally, the ZCD and Trioplex real-time RT-PCR assays detecting Zika, chikungunya, and dengue viruses both yielded a sensitivity of 96.1% and specificity of 100%. Together, these assays resolve the urgent need for diagnostic and surveillance tools for countries affected by Zika virus infections.

6 October 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
LKLeah C. Katzelnick
Leah C. Katzelnick
JZJose Victor Zambrana
Jose Victor Zambrana
DEDouglas Elizondo
Douglas Elizondo
DCDamaris Collado
Damaris Collado
NGNadezna Garcia
Nadezna Garcia
EHEva Harris
Eva Harris
Unexpectedly, cross-reactive antibodies are stable or rise after primary dengue and Zika virus infection and wane slowly after secondary infection.

29 May 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
JZJose Victor Zambrana
Jose Victor Zambrana
CHChloe M. Hasund
Chloe M. Hasund
RARosemary A. Aogo
Rosemary A. Aogo
SBSANDRA BOS
SANDRA BOS
SASonia Arguello
Sonia Arguello
EHEva Harris
Eva Harris
Infection with any of the four dengue virus serotypes (DENV1–4) can protect against or enhance subsequent dengue depending on preexisting antibodies and infecting serotype. Additionally, primary infection with the related flavivirus Zika virus (ZIKV) is associated with increased risk of DENV2 disease. Here, we measured how prior DENV and ZIKV immunity influenced risk of disease caused by DENV1–4 in a pediatric Nicaraguan cohort. Of 3412 participants in 2022, 10.6% experienced dengue cases caused by DENV1 ( n = 139), DENV4 ( n = 133), DENV3 ( n = 54), DENV2 ( n = 9), or an undetermined serotype ( n = 39). Longitudinal clinical and serological data were used to define infection histories, and generalized linear and additive models adjusted for age, sex, time since last infection, and year, and repeat measurements were used to predict disease risk. Compared with flavivirus-naïve participants, primary ZIKV infection was associated with increased risk of disease caused by DENV4 (relative risk = 2.62, 95% confidence interval: 1.48 to 4.63) and DENV3 (2.90, 1.34 to 6.27), but not DENV1 infection. Primary DENV infection or DENV followed by ZIKV infection was also associated with increased risk of DENV4 disease. We reanalyzed 19 years of cohort data and demonstrated that prior flavivirus immunity and antibody titer had distinct associations with disease risk depending on incoming serotype. We thus find that prior ZIKV infection, like prior DENV infection, is associated with increased risk of disease with certain DENV serotypes. Cross-reactivity among flaviviruses should be considered when assessing vaccine safety and efficacy.